Positive results from phase III LINC 4 study reinforce the efficacy and safety of Isturisa in Cushing's disease. -Recordati
Recordati Rare Diseases announces that positive results from the Phase III LINC 4 study of Isturisa were presented on March 22 at the Endocrine Society’s Annual Meeting. Results from LINC 4, the first Phase III study in patients with Cushing’s disease to include an upfront, double-blind, randomised, placebo controlled period, demonstrated that Isturisa provided rapid and sustained normalisation of mean urinary free cortisol (mUFC) levels.